The challenges facing the UK neurorehabilitation charity sector
By Natalie Mackenzie, Director, BIS Services
By Natalie Mackenzie, Director, BIS Services
From an estate planning perspective, the prediction of a future [...]
Article by Eddie Jones, Partner in Medical Negligence at JMW [...]
By Laura Porter, Professional Mentor at ILS I qualified as [...]
"The recent advancements in neurotechnology will significantly transform various aspects of society, offering profound implications for healthcare, communication, and human capabilities" - Alexandrea Day, CEO of MetaBrain Labs
By Norman Putzki (MD PhD), global head development neuroscience and gene therapy at Novartis.
Over the last 30 years, remarkable progress has been made in the advancement of treating multiple sclerosis (MS), a potentially disabling disease that is most likely a consequence of complex autoimmune dysfunctions in the periphery ultimately leading to demyelination in the central nervous system (CNS).
Since 1993, a series of insights has led to greater understanding of the biological mechanisms and triggers driving the inflammatory attacks on the CNS.
These translational insights have also driven the development of newer and more effective treatments in MS.